文章摘要
杜喜维,吴 娟,孙 宝,晋亚楠,杨 越,曹小雨,杨瑞霞.门冬胰岛素联合甘精胰岛素对新诊断2型糖尿病患者炎性因子、血糖及血脂水平的影响[J].,2020,(12):2342-2345
门冬胰岛素联合甘精胰岛素对新诊断2型糖尿病患者炎性因子、血糖及血脂水平的影响
Effect of Insulin Aspart and Insulin Glargine on the Inflammatory Factor, Blood Lipid and Glucose Levels in the Newly Diagnosed Type 2 Diabetic Patients
投稿时间:2019-12-02  修订日期:2019-12-27
DOI:10.13241/j.cnki.pmb.2020.12.031
中文关键词: 门冬胰岛素  甘精胰岛素  新诊断2型糖尿病  炎性因子  血糖  血脂
英文关键词: Insulin aspart  Insulin glargine  Newly diagnosed type 2 diabetes  Inflammatory factor  Blood glucose  Blood lipid
基金项目:陕西省科技厅科研基金项目(2017SF-093)
作者单位E-mail
杜喜维 西安医学院第二附属医院药剂科 陕西 西安 710038 duxiw1234@163.com 
吴 娟 西安医学院第二附属医院全科医疗科 陕西 西安 710038  
孙 宝 西安医学院第二附属医院药剂科 陕西 西安 710038  
晋亚楠 西安医学院第二附属医院药剂科 陕西 西安 710038  
杨 越 西安医学院第二附属医院药剂科 陕西 西安 710038  
曹小雨 西安医学院第二附属医院药剂科 陕西 西安 710038  
杨瑞霞 西安医学院第二附属医院药剂科 陕西 西安 710038  
摘要点击次数: 7
全文下载次数: 9
中文摘要:
      摘要 目的:探讨门冬胰岛素联合甘精胰岛素对新诊断2型糖尿病患者血清炎性因子、血糖及血脂水平的影响。方法:选取我院2017年3月~2019年3月收治的100例新诊断2型糖尿病患者,将其随机分为研究组和对照组,每组50例患者。对照组患者给予门冬胰岛素治疗,研究组患者给予门冬胰岛素联合甘精胰岛素治疗,对比两组患者治疗前后血清炎性因子、血糖及血脂水平的变化。结果:治疗后,两组患者糖化血红蛋白(hemoglobin A1c,HbA1c)、空腹血糖(fasting plasma glucose,FPG)、餐后2h血糖(2h postprandial blod glucose,2hPBG)、血清肿瘤坏死因子(Tumor necrosis factor,TNF-α)、高敏C反应蛋白(high-sensitive C-reactive protein,hs-CRP)水平均较治疗前明显降低(P<0.05),且研究组患者以上指标均显著低于对照组(P<0.05);两组患者治疗后总胆固醇(Total Cholesterol,TC)、甘油三酯(Triglyceride,TG)、低密度脂蛋白胆固醇(Low-density lipoprotein cholesterol,LDL-C)水平均较治疗前明显降低,高密度脂蛋白胆固醇(High-density lipoprotein cholesterol,HDL-C)明显升高(P<0.05),且研究组以上指标的改善程度均优于对照组(P<0.05)。研究组患者的胰岛素用量明显少于对照组(P<0.05),患者血糖首次达标时间明显短于对照组(P<0.05)。结论:门冬胰岛素联合甘精胰岛素适用于新诊断2型糖尿病患者,可有效降低血糖、血脂、血清TNF-α和hs-CRP水平。
英文摘要:
      ABSTRACT Objective: To investigate the effects of insulin aspart and insulin glargine on the serum inflammatory factor, blood glucose and blood lipid levels in the newly diagnosed type 2 diabetic patients. Methods: One hundred patients with newly diagnosed type 2 diabetes admitted from March 2017 to March 2019 in our hospital were randomly divided into study group and control group, with 50 patients in each group. The control group received insulin aspart and the study group received insulin aspart and insulin glargine. The changes of serum inflammatory factors, blood glucose and blood lipid levels before and after treatment were compared between the two groups. Results: After treatment, the HbA1c, FPG, 2hPBG, TNF-α, and hs-CRP of both groups of patients were significantly lower than those before treatment (P<0.05), and the above indexes of study group were significantly lower than those of the control group (P<0.05). The levels of TC, TG and LDL-C in both groups were significantly lower than those before treatment, and HDL-C was significantly increased (P<0.05), and the improvement of the above indexes in the study group was better than that in the control group (P<0.05). The insulin dosage of the study group was significantly lower than that in the control group (P<0.05). The first time of blood glucose compliance in the study group was significantly shorter than that in the control group (P<0.05). Conclusion: Insulin aspart and insulin glargine are suitable for patients with newly diagnosed type 2 diabetes, which can effectively lower the blood glucose, blood lipids, serum TNF-α and hs-CRP levels.
查看全文   查看/发表评论  下载PDF阅读器
关闭